Effect of 6-diazo-5-oxo-L-norleucine (DON) on human carcinoid tumor cell aggregates

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2363-2367

  Wu, Feng ^a,b   Bergström, Mats ^a,b,c   Stridsberg, Mats ^c   Örlefors, Håkan ^c   Eriksson, Barbro ^c   Öberg, Kjell ^c   Watanabe, Yasuyosht ^a,b   Långstrom, Bengt ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carcinoid tumors; Chromogranin; Diazo oxo norleucine; Glutamine antagonists; Multicellular aggregates

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; CHROMOGRANIN A; GLUTAMIC ACID; GLUTAMINE; METHIONINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CARCINOID; CELL AGGREGATION; CELL GROWTH; CELL SECRETION; CONTROLLED STUDY; DRUG EFFECT; GLIOMA; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROSECRETORY CELL; PANCREAS CANCER; PRIORITY JOURNAL;

2-AMINOADIPIC ACID; BIOLOGICAL TRANSPORT; CARCINOID TUMOR; CELL AGGREGATION; CHROMOGRANIN A; CHROMOGRANINS; DIAZOOXONORLEUCINE; HUMANS; METHIONINE; SEROTONIN; TUMOR CELLS, CULTURED;

EID: 0030857220     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Praida N: Enzyme targets of antiglutamine agents in cancer chemotherapy. Adv Enz Reg 24: 207-222, 1985.
2. Ahluwalia GS, Grem JL, Hao Z and Cooney DA: Metabolism and action of amino acid analogue anti-cancer agents. Pharmac Ther 46: 243-271, 1990.
3. Griffiths M, Keast D, Patrick G, Crawford M and Palmer TN: The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukemia in vitro. Int J Biochem 25: 1749-1755, 1993.
4. Dranoff G, Elion GB, Friedman HS, Campbell GL and Bigner DD: Influence of glutamine on the growth of human glioma and medulloblastoma in culture. Cancer Research 45: 4077-4081, 1985.
5. Earhart RH, Amato DJ, Chang AY, Borden EC et al: Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Invest New Drug 8: 113-119, 1990.
6. Sullivan MP, Nelson JA, Feldman S and Van Nguyen B: Pharmacokinetic and phase I study of intravenous DON (6-diazo5- oxo-L-norleucine) in children. Cancer Chemother Pharmacol 21: 78-84, 1988.
7. Rahman A, Smith FP, Luc TH and Wooley PV: Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON). Invest New Drugs 3: 369-374, 1985.
8. Ruhin J, Sorensen S, Schutt AJ, van Hazel GA, O'Connell MJ and Moertel CG: A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma. Am J Clin Oncol 6: 325-326, 1983.
9. Lynch G, Kemeny N and Casper E: Phase II evaluation of DON (6- diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma. Am J Gin Oncol 5: 541-543, 1982.
10. Eagan RT, Frytak S, Nichols WC, Creagan ET and Ingle JN: Phase II study on DON in patients with previously treated advanced lung cancer. Cancer Treat Rep 60: 1665-1666, 1982.
11. Earhart RH, Koeller JM and Davis HL: Phase I trial of 6-diazo5-oxo-L-norleucine (DON) administered by 5-day courses. Cancer Treat Rep 66: 1215-1217, 1982.
12. Kovach JS, Eagan RT, Powis G, Rubin J, Creagan ET and Moertel CG: Phase I and pharmacokinetic studies of DON. Cancer Treat Rep 65: 1031-1036, 1981.
13. Ahnert-Hilger G, Grube K, Kvols L et al: Gastroenteropancreatic neuroendocrine tumors contain a common set of synaptic vesicle proteins and amino acid neurotransmitters. Eur J Cancer 29: 1982- 1984, 1993.
14. Evers BM, Ishizuka J, Townsend CM Jr and Thompson JC: The human carcinoid cell line BON. A model system for the study of carcinoid tumors. Ann New York Acad Sci 1994. pp 393-406.
15. Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240: 117256 1988.
16. 11C)-methionine in the multicellular spheroid system. J Nucl Med 32: 2258-2265, 1991.
17. Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K and Oberg K: Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 139: 329-337, 1993.
18. Iozzo RV and Clark CC: Modulation of heparan sulfate biosynthesis. Effects of 6-diazo-5-oxo-L-norleucine and low glutamine on the synthesis of heparan sulfate proteoglucan by human colon carcinoma cells. J Biol Chem 262: 11188-11199, 1987.
19. Clark CC, Richards CF, Pacifici M and Iozzo RV: The effects of 6- diazo-5-oxo-L-norleucine a glutamine analogue on the structure of the major cartilage proteoglucan synthesized by cultured chondrocytes. J Biol Chem 262: 10229-10238 1987.
20. Aharony D and Dobson P: Discriminative effect of gammaglutamyl transpeptidase inhibitors on metabolism of leukotriene C4 in peritoneal cells. Life Sci 35: 2135-2142, 1984.
21. Gati I, Bergström M, Muhr C and Carlsson J: Leukotriene and 5- lipoxygenase inhibitor induced variations in thymidine uptake in a human glioma cell line cultured as monolayers or as multicellular spheroids. Anticancer Res 14: 453-460, 1994.